Analysts forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will post earnings of ($0.37) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Leap Therapeutics’ earnings. Leap Therapeutics posted earnings per share of ($0.46) during the same quarter last year, which would indicate a positive year over year growth rate of 19.6%. The business is scheduled to issue its next earnings report on Friday, May 10th.
According to Zacks, analysts expect that Leap Therapeutics will report full-year earnings of ($1.57) per share for the current year. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Leap Therapeutics.
Several equities research analysts recently issued reports on LPTX shares. Raymond James cut their price objective on Leap Therapeutics from $13.00 to $8.00 and set an “outperform” rating on the stock in a report on Wednesday, December 19th. ValuEngine downgraded Leap Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Finally, Zacks Investment Research upgraded Leap Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th.
In related news, CEO Christopher Mirabelli purchased 571,428 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were bought at an average price of $1.75 per share, for a total transaction of $999,999.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 58.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of LPTX. Virtu Financial LLC acquired a new position in shares of Leap Therapeutics during the 4th quarter worth about $28,000. JPMorgan Chase & Co. acquired a new position in shares of Leap Therapeutics during the 3rd quarter worth about $111,000. Renaissance Technologies LLC boosted its position in shares of Leap Therapeutics by 23.5% during the 3rd quarter. Renaissance Technologies LLC now owns 138,868 shares of the company’s stock worth $1,082,000 after acquiring an additional 26,401 shares in the last quarter. FMR LLC boosted its position in shares of Leap Therapeutics by 3.9% during the 4th quarter. FMR LLC now owns 957,124 shares of the company’s stock worth $1,914,000 after acquiring an additional 36,300 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Leap Therapeutics by 45.7% during the 4th quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock worth $248,000 after acquiring an additional 39,000 shares in the last quarter. Institutional investors own 9.08% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Further Reading: What are the Different Types of Leveraged Buyouts?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.